At Annion, our portfolio management methodology begins with a thorough analysis of the company's current business landscape and a comprehensive understanding of its long-term strategic objectives. Once this foundation is established, we conduct a meticulous evaluation of potential APIs for inclusion in the product portfolio. Our initial assessment covers a range of factors, including technical complexity, therapeutic relevance, patent status, and regulatory requirements, to ensure a strategic and informed selection.

Following this, we prioritize projects based on in-depth market analysis and forecasting, examining demand, competition, and pricing trends to identify growth opportunities. Our bespoke optimization process is designed to meet the unique needs of each client, employing a refined methodology to evaluate and select APIs based on carefully curated criteria. This ensures that only the most promising compounds advance to the next stage of development. Our personalized approach and extensive know how guarantees precision in decision-making and maximizes the potential for success at every phase.

Annion’s elevated skillset to visualize the full potential of APIs enables us to offer an exclusive lifecycle management service, meticulously overseeing each API from initial development and launch through to market maturity. With our dynamic approach, we make strategic decisions aimed at maximizing the value of selected products through all its lifecycle.

At Annion, we offer comprehensive portfolio management services for Finished Dosage Forms (FDFs), using a methodology comparable to our approach for APIs. We start by understanding the client's strategic goals and available capabilities, allowing us to define a tailored portfolio that aligns with their objectives. Our process begins with a meticulous evaluation of potential products, assessing factors like technical complexity, therapeutic relevance, patent status, and regulatory requirements to ensure a strategic and informed selection. We then prioritize projects through in-depth market analysis and forecasting, examining demand, competition, and pricing trends to identify the products that best fit the company’s strategy.  We adapt our methodology to meet the unique needs of each customer, considering factors such as investment budgets and development timeframes. Our refined approach evaluates and selects drugs based on carefully curated criteria to ensure optimal alignment with our clients' strategic objectives. This ensures that only the most promising compounds are selected and included in the portfolio. Our personalized approach and extensive know how guarantees precision in decision-making and maximizes the potential for success at every phase.

At Annion, we guide our clients in developing a portfolio of Value-Added Medicines (VAMs)* and 505(b)(2) products**. Our methodology begins by identifying opportunities that align with the company’s innovation goals and investment strategies. These opportunities are then evaluated based on their scientific, medical, and commercial potential, as well as their regulatory requirements.

The complexity of identifying opportunities in this area makes it a priority to ensure alignment and close teamwork with the client.

*Value-Added Medicines are medicines based on known molecules that address healthcare needs and deliver relevant improvement for patients, healthcare professionals and/or payers.

**The 505(b)(2) is a U.S. regulatory pathway for new drug applications based on already approved molecules, allowing the use of existing preclinical and clinical data to streamline the approval process.